Dasatinib or high-dose imatinib for chronic-phase chronic...

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily : Two-year follow-up of a randomized phase 2 study (START-R)

Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, Saengsuree Jootar, Jerzy Holowiecki, Nelson Hamerschlak, Timothy Hughes, Eric Bleickardt, David Dejardin, Jorge Cortes, Neil P. Shah
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
115
Year:
2009
Language:
english
Pages:
12
DOI:
10.1002/cncr.24504
File:
PDF, 297 KB
english, 2009
Conversion to is in progress
Conversion to is failed